The Role of the Laboratory in the Diagnosis of Rheumatoid Arthritis
Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
August 2011
As a result of the initial studies, development of clinical assays for anti-citrullinated protein antibodies focused on improving assay sensitivity while maintaining the high specificity.
This was accomplished through optimization of the protein or proteins used as the target antigen.
During the course of this work, it was discovered that formation of a cyclic peptide improved the sensitivity of the assays.
To form these circularized structures, cysteine residues were placed on either end of the peptide. When a disulfide bond is formed between the 2 cysteine residues, a cyclic peptide results. This is where the term “anti-cyclic citrullinated peptide antibody” or “anti-CCP antibody” come from. It is thought that the cyclic structure allows for maximum exposure of the citrullinated residue.
Development of Clinical Assays |
Jump to section:
- Introduction
- Introduction to Rheumatoid Arthritis
- Risk Factors Associated with Development of Rheumatoid Arthritis
- Clinical Symptoms of Rheumatoid Arthritis
- 1987 Classification Criteria for Rheumatoid Arthritis
- 2010 Classification Criteria for Rheumatoid Arthritis
- Laboratory Evaluation of Patient with RA
- Utility of Rheumatoid Factor
- Discovery of Anti-Citrulline Antibodies
- Enzymatic Process of Citrullination
- Diagnostic Performance of Anti-Citrulline Antibodies
- Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
- Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
- Sensitivity and Specificity Comparison Anti-CCP and RF
- Summary
- Questions?
External
link
PDF
document
Excel
document
Word
document